Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers

Phase I/II Clinical Trial to Be Initiated in First Quarter 2021 CAMBRIDGE, Mass., Feb. 23, 2021 -- (Healthcare Sales & Marketing Network) -- Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on i... Biopharmaceuticals, Oncology, FDA Elicio Therapeutics, Amphiphile, KRAS, pancreatic ductal adenocarcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news